Fig. 2: Association of immune infiltrates with patient prognosis.
From: Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer
a Unsupervised hierarchical clustering of 92 treatment-naive tumour samples based on the quantification of evaluated immune markers. Four clusters were defined, which were named ‘immuno-active’ (cluster 1), ‘immuno-medial’ (cluster 2), ‘immuno-deficient’ (cluster 3), and ‘immuno-NK (cluster 4). b Representative images of immunohistochemical staining for the ‘immuno-active’ cluster. c Representative images of immunohistochemical staining for the ‘immuno-medial’ cluster. d Representative images of immunohistochemical staining for the ‘immuno-deficient’ cluster. e Representative images of immunohistochemical staining for the ‘immuno-NK cluster. f Prognostic value of immune subtyping in cervical cancer as indicated by Kaplan–Meier curves of progression-free survival (PFS). P value was based on the log-rank test. g Immunohistochemical staining of the indicated immune markers in typical tertiary lymphoid structures. h Prognostic value of tertiary lymphoid structures (TLS) in cervical cancer as indicated by Kaplan–Meier curves of progression-free survival (PFS). P value was based on log-rank test.
